Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This preclinical study found that Mesenchymal Stem Cell-derived Conditioned Media formulations were safe and effective in rat and mouse models for treating chemotherapy- and radiation-induced oral mucositis, demonstrating improved tissue regeneration and healing, most notably at higher concentrations.

This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.

In this study, the combination of pulse intravenous corticosteroids and methotrexate was associated with positive hair regrowth in severe alopecia areata patients, with half achieving total regrowth.

The study reported that topical 0.1% tacrolimus improved proliferative and necrotizing otitis externa in cats, with complete lesion resolution in some cases.

Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

This case report describes a 32-year-old man who developed SCC of the common bile duct a year after receiving treatment for a malignant proliferating trichilemmal tumour on the scalp.

Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.

This case report observed that treatment with human placental mesenchymal stromal cell-derived exosome-enriched extracellular vesicles may improve symptoms of chronic cutaneous graft-versus-host disease, including hyperpigmentation and skin ulcers, in a patient resistant to conventional therapies.

This study found that inhibiting EGFR signaling in mice can prevent alopecia caused by cyclophosphamide treatment, highlighting its potential role in managing chemotherapy-induced hair loss.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

In this study, combining pemetrexed with cisplatin in non-small cell lung cancer patients improved immune function and had lower blood toxicity compared to cisplatin with gemcitabine, despite similar disease control rates and other side effects between the two treatment groups.

This study suggests that BRAF inhibitors, particularly Encorafenib and Dabrafenib, may have potential applications in wound healing by targeting specific proteins involved in the healing process in murine models.

In this case report, two patients with coexisting systemic lupus erythematous and neuromyelitis optica spectrum disorder achieved remission of SLE activity using an anti-CD19 monoclonal antibody.

Platelet-rich plasma doesn't prevent hair loss from chemotherapy, and mononuclear cells only help against hair loss from one specific chemotherapy drug.

This case study reports a 70-year-old man with treatment-resistant pityriasis rubra pilaris achieving complete clinical remission with ustekinumab, adding to evidence supporting biologic therapy when TNF inhibitors are unsuitable.

This study found that methylprednisolone pulse therapy may be an effective treatment option for patients with severe multifocal alopecia areata, particularly those experiencing their first episode.

In this study, researchers developed a collagen and bacterial cellulose-based dressing loaded with bacitracin, which exhibited enhanced antibacterial activity, improved wound healing, and reduced inflammation in a murine infected-wound model, suggesting its potential for clinical use in treating infected wounds.

The committee unanimously voted against recommending approval of the injectable cisplatin/epinephrine gel IntraDose for certain head and neck cancer patients, citing insufficient clinical benefit and concerns about toxicity in this study.

This study reported that therapeutic make-up significantly improves the long-term quality of life for patients with facial dermatoses, showing a sustained benefit one year after application, particularly in younger patients.

This study suggests that using cell-free dexamethasone-primed stem cell media may offer a promising alternative treatment for systemic lupus erythematosus, showing immunomodulatory benefits and therapeutic efficacy in reducing various complications.

This study found that the combination of letrozole and quercetin loaded in spanlastics showed enhanced cytotoxicity and other anticancer effects against MCF-7 breast cancer cells compared to individual treatments.

This study found that tofacitinib may be effective in treating various pediatric rheumatic diseases, particularly juvenile idiopathic arthritis, although some patients did not respond, and side effects were observed.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

In this study, tacrolimus was as effective as clobetasol propionate in treating alopecia areata, suggesting it can serve as an alternative therapy option.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

This case study demonstrated that off-label tofacitinib treatment led to full regrowth of scalp hair after 18 months in a patient with alopecia areata universalis, following unsuccessful therapies.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.